Blog

Jan 14, 2025, 02:50

Phase 1b study of telisotuzumab vedotin in combination with osimertinib for NSCLC

Yakup Ergün Medical Oncologist at Antalya City Hospital shared on X:

“Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met–overexpressing, EGFR-mutated locally advanced/metastatic NSCLC after progression on prior osimertinib

ORR 50%
G3-4 Pulmonary embolism 8%!”

Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib – Annals of Oncology

Authors: H. Horinouchi, B.C. Cho, D.R. Camidge, K. Goto, P. Tomasini, Y. Li, A. Vasilopoulos, P. Brunsdon, D. Hoffman, W. Shi, E. Bolotin, V. Blot, J. Goldman

Phase 1b study of telisotuzumab vedotin in combination with osimertinib for NSCLC

A. Vasilopoulos B.C. Cho cancer D. Hoffman D.R. Camidge E. Bolotin H. Horinouchi J. Goldman K. Goto NSCLC OncoDaily Oncology P. Brunsdon P. Tomasini V. Blot W. Shi Y. Li Yakup Ergün

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage